Zantac litigation
Lawsuits allege that ranitidine, the active ingredient in Zantac, can degrade into NDMA, a probable human carcinogen, and that manufacturers knew of the risk for decades.
Free case review
What the lawsuits allege
In 2019, independent testing found N‑nitrosodimethylamine (NDMA) in ranitidine products, and the FDA requested the removal of all ranitidine from the United States market in 2020. The litigation alleges that the molecule is inherently unstable and that manufacturers failed to warn consumers that NDMA could form in the drug itself.
Many claims have resolved and others continue in state courts. Eligibility depends on the cancer type, your history of Zantac use, and your state.
Injuries named in the litigation
- Bladder cancer
- Stomach (gastric) cancer
- Esophageal cancer
- Liver and pancreatic cancer
Who may qualify
If you regularly used brand-name Zantac before the 2020 recall and were later diagnosed with bladder, stomach, esophageal, liver, or pancreatic cancer, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you. Deadlines vary significantly by state, so it is worth asking sooner rather than later.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.